Group 1: Company Overview - The company operates in eight major application areas: animal nutrition and health, human nutrition and health, care and cleaning, bioenergy, food and beverage, pulp and paper, textiles and leather, and environmental and ecological agriculture [2][3]. Group 2: Financial Performance - In 2024, the company achieved a revenue of 826 million CNY, a year-on-year increase of 3.79%, and a net profit of 31.09 million CNY, marking a turnaround from losses [3][6]. - In Q1 2025, the company reported a revenue of 202 million CNY, a year-on-year growth of 1.79%, but a net profit of 4.87 million CNY, which represents a decline of 75.19% compared to the previous year [3][6]. Group 3: Operational Efficiency - The company implemented "cost reduction and efficiency enhancement" strategies, resulting in decreased production and procurement costs, thereby improving product competitiveness [3][6]. - The company has established multiple intelligent production bases in Guangdong, Inner Mongolia, and Hunan, enhancing its operational capabilities [4][6]. Group 4: Research and Development - The company has significantly increased R&D investment, achieving breakthroughs in various enzyme products and securing 22 patents across Asia, Europe, and America [5][6]. - Future growth will focus on three main areas: bio-enzymes, plant extracts, and biosynthetic products, emphasizing innovation, market expansion, and cost efficiency [6][9]. Group 5: Industry Outlook - The bio-manufacturing sector is expected to experience sustained high-quality growth, supported by national policies aimed at advancing technology and industry development [9]. - The livestock industry in China is stabilizing, with a shift towards centralized farming practices, which is anticipated to contribute to overall industry stability [9].
溢多利(300381) - 300381溢多利投资者关系管理信息20250425